Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2011. The report details a specific share repurchase transaction executed on April 18, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 550,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,250 pence per share; lowest price paid was 1,238.5 pence per share.
- Treasury Holdings: Following cancellation, GSK holds 493,224,284 shares in Treasury.
- Treasury Percentage: Represents 8.72% of total issued share capital and 9.55% of total voting rights.
- Shares in Issue: 5,164,145,450 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's issued share capital through the cancellation of 550,000 repurchased shares. Consequently, the proportion of Treasury shares held by the Company now represents 8.72% of the total issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,164,145,450) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (493,224,284) and its impact on voting rights (9.55%).
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial results.